Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
RMD Open|March 4, 2026
Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA studyPeter C Taylor, Georg Schett, Tom W J Huizinga, et al.
Rheumatology and Therapy|December 26, 2025
Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS)Edwin Lam, Katherine Berezny, Corey J Bishop, et al.
Clinical Pharmacology in Drug Development|May 1, 2023
A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine KinaseJocelyn H Leu, Xin Miao, Kevin Shalayda, et al.
American Journal of Perinatology|August 28, 2024
Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and NewbornYosuke Komatsu, E J T Joanne Verweij, Eleonor Tiblad, et al.
Genome Research|March 10, 2009
Complete genome of the cellulolytic thermophile Acidothermus cellulolyticus 11B provides insights into its ecophysiological and evolutionary adaptationsRavi D Barabote, Gary Xie, David H Leu, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 17, 2023
Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial DesignLaura E Schanberg, Lily Yeruk Mulugeta, Bolanle Akinlade, et al.
The Journal of Rheumatology|August 5, 2025
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III StudyHermine I Brunner, César Pacheco-Tena, Ingrid Louw, et al.
NEJM Evidence|January 27, 2026
Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and NewbornDerek P de Winter, Kenneth J Moise, Leona E Ling, et al.
The Journal of Rheumatology|August 1, 2024
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III StudyHermine I Brunner, César Pacheco-Tena, Ingrid Louw, et al.
Pageof 10